Labetuzumab govitecan

Labetuzumab govitecan

Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer.

 

 

 

[accordions]
[accordion title= “Chemical Properties“]

Synonyms IMMU130, Labetuzumab-SN38, hMN14-SN38, IMMU 130, IMMU-130
Molecular Weight 1587.76
Formula C75H102N12O24S
CAS No. 1469876-18-3

[/accordion]

 

 

 

[accordions]
[accordion title= “References and Literature“]

1. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, Guarino MJ, Marshall JL, Goldberg RM, Hecht JR, Wegener WA, Sharkey RM, Govindan SV, Goldenberg DM, Berlin JD. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. doi: 10.1200/JCO.2017.73.9011. Epub 2017 Aug 17. PubMed PMID: 28817371.

[/accordion]